Clearmind Medicine Meets with FDA to Discuss Clinical Trial in Alcohol Use Disorder; Shares Up 72%
Clearmind Medicine (Nasdaq: CMND) has completed a Type A meeting with the FDA to discuss the Company’s clinical trial of CMND-100 for the treatment of Alcohol Use Disorder treatment (AUD) using its novel psychedelic- based therapy. Yale School of Medicine’s Department of Psychiatry was announced as the first US-based clinical site to join the company’s first-in-human Phase I/IIa trial in May 2023. The company’s share price rose 72% in morning trading on Wednesday.
Commenting on the meeting, Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine, said, “The meeting was informative and productive, and we’re eager to advance the U.S. regulatory process and potentially bring a new hope for millions suffering from AUD by providing an innovative approach to overcome the challenges associated with the current available treatments to date.”
CMND-100’s active ingredient, known as MEAI (5-methoxy-2-aminoindane), is a novel psychoactive molecule that has been reported to reduce the desire to consume alcoholic beverages while exerting a euphoric alcohol-like experience.
About Clearmind Medicine Inc.
Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.
The Company’s intellectual portfolio currently consists of fifteen patent families. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
